[{"id":"ee15de22-b96e-4782-9dfa-de6fb61fba65","acronym":"MoST-TAP","url":"https://clinicaltrials.gov/study/NCT06003621","created_at":"2023-08-22T15:08:28.367Z","updated_at":"2024-07-02T16:35:00.422Z","phase":"Phase 2","brief_title":"Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients","source_id_and_acronym":"NCT06003621 - MoST-TAP","lead_sponsor":"Omico","biomarkers":" PD-L1 • TMB • CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression • PD-L1 amplification","tags":["PD-L1 • TMB • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Pegasys (pegylated interferon α -2a) • tiragolumab (RG6058)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 12/15/2023","start_date":" 12/15/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2024-05-29"},{"id":"07c7a5d9-df0c-45c5-9b74-abae8c8d1379","acronym":"","url":"https://clinicaltrials.gov/study/NCT03751761","created_at":"2021-01-18T18:23:38.922Z","updated_at":"2024-07-02T16:35:17.456Z","phase":"Phase 1/2","brief_title":"GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study","source_id_and_acronym":"NCT03751761","lead_sponsor":"Asan Medical Center","biomarkers":" PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PD-L1 amplification • POLD1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation","tags":["PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PD-L1 amplification • POLD1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 06/11/2018","start_date":" 06/11/2018","primary_txt":" Primary completion: 08/30/2023","primary_completion_date":" 08/30/2023","study_txt":" Completion: 08/30/2023","study_completion_date":" 08/30/2023","last_update_posted":"2024-02-28"},{"id":"acb2717e-a36e-41ca-907e-430b8037d287","acronym":"","url":"https://clinicaltrials.gov/study/NCT03012230","created_at":"2021-01-18T14:49:16.634Z","updated_at":"2024-07-02T16:35:21.613Z","phase":"Phase 1","brief_title":"Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer","source_id_and_acronym":"NCT03012230","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • PD-L1 • ER • PGR • JAK2 • PD-L2","pipe":" | ","alterations":" PD-L1 expression • PD-L1 amplification • PGR expression","tags":["HER-2 • PD-L1 • ER • PGR • JAK2 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 amplification • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Jakafi (ruxolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/06/2017","start_date":" 12/06/2017","primary_txt":" Primary completion: 01/06/2023","primary_completion_date":" 01/06/2023","study_txt":" Completion: 03/08/2023","study_completion_date":" 03/08/2023","last_update_posted":"2024-01-31"}]